ChemicalBook >> CAS DataBase List >>AHU-377

AHU-377

CAS No.
149709-62-6
Chemical Name:
AHU-377
Synonyms
Sacubitril(AHU-377);Sacubitril API;valsartan/sacubitril Impurity 1;LCZ697;AHU-77;AHU-37;AHU-377;SACUBRITIL;LCZ-696-007-2S4R;Sacubtril(LCZ696)
CBNumber:
CB62627304
Molecular Formula:
C24H29NO5
Molecular Weight:
411.49
MOL File:
149709-62-6.mol

AHU-377 Properties

Boiling point 656.9±55.0 °C(Predicted)
Density 1.151±0.06 g/cm3(Predicted)
storage temp. Sealed in dry,Store in freezer, under -20°C
pka 4.72±0.10(Predicted)

AHU-377 price More Price(23)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
TRC S080895 Sacubitril 149709-62-6 250mg $580 2021-12-16 Buy
TRC S080895 Sacubitril 149709-62-6 500mg $1115 2021-12-16 Buy
Matrix Scientific 132790 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoicacid 97% 149709-62-6 5g $1980 2021-12-16 Buy
ApexBio Technology B1070 AHU-377(Sacubitril) 149709-62-6 50mg $885 2021-12-16 Buy
Matrix Scientific 132790 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoicacid 97% 149709-62-6 1g $648 2021-12-16 Buy
Product number Packaging Price Buy
S080895 250mg $580 Buy
S080895 500mg $1115 Buy
132790 5g $1980 Buy
B1070 50mg $885 Buy
132790 1g $648 Buy

AHU-377 Chemical Properties,Uses,Production

Pharmacologic action

AHU377 and angiotensin IIAT1 receptor antagonist valsartan at a molar ratio of 1: 1 compose LCZ696. LCZ696 was a dual inhibitor of angiotensin II (AT2) receptor and enkephalinase (Neprilysin) receptor. And with its better antihypertensive efficacy than standard antihypertensive drugs, it is a new drug for the treatment of heart failure.
AHU377 is a prodrug that converts the active form of the enzyme cleavage LBQ657 ethyl ester. So far its efficacy and safety in milestone phase III surpass the clinical standard drug enalapril.
In a clinical trial of the drug, 100 to 400 mg of combined drugs, 80 to 320 mg of valsartan, 200 mg of neprilysin inhibition or placebo were given to the patients in the double-blind trial of phase two with mild to moderate hypertension. The combined drugs are more effective and better tolerated with no vascular edema report than solely applied valsartan or other drugs. LCZ696 shows sustainable treatment benefits in the early treatment:
(1) a 20% reduction in the risk of death from cardiovascular disease (p = 0.00004).
(2) hospitalization for heart failure was reduced by 21% (p = 0.00004).
(3) all-cause mortality was reduced by 16% (p = 0.0005).
(4) The overall risk is reduced by 20% according to the composite measure of the primary endpoint of hospitalization for cardiovascular death or heart failure (p = 0.0000002).

Novartis’ New Angiomyocardiac LCZ696

According to a recent study published by Novartis, LCZ696, a cardiovascular drug being developed by the company, will become a new hope for the company. The current study shows that this drug functions well in the remission of cardiovascular necrosis and other symptoms caused by heart disease.
LCZ696 is a combination of Novartis Diovan and AHU-377. Some analysts have spoken highly of the drug and estimated that it might be submitted to the FDA as early as next year. Once confirmed in the audit it will mark another great step forward of Novartis in the field of cardiovascular drugs.
Although it showed high expectations to LCZ696, Novartis still has a long way to go, given the setbacks of its serelaxin in the FDA and the European Medicines Administration.
The news came straight from Basel as investigators around the world were wrapping up the big scientific meeting of the American College of Cardiology.

Market analysis

In the field of research and development of drugs, most of the success of the new drugs in phase II will always lead to a series of competitor projects. The LCZ696 performs so prominently that the industry was shocked. It is predicted that few cardiovascular drugs will be qualified to compete with the LCZ696 in the next few years. Some analysts predict that the LCZ696 sales will peak at $ 8 billion, while Deutsche Bank analysts expect the drug to peak at $ 6 billion, given LCZ696's superior performance in reducing cardiovascular risk. Although the data are slightly different, there is no doubt that, LCZ696 will become a super star to lead the cardiovascular treatment to step into a new era.

108-30-5
149690-12-0
149709-62-6
Synthesis of AHU-377 from Succinic anhydride and (2R,4S)-4-Amino-5-(biphenyl-4-yl)-2-methylpentanoic Acid Ethyl Ester Hydrochloride
Global( 189)Suppliers
Supplier Tel Email Country ProdList Advantage
Capot Chemical Co.,Ltd.
571-85586718 +8613336195806 sales@capotchem.com China 19994 60
Henan DaKen Chemical CO.,LTD.
+86-371-66670886 info@dakenchem.com China 16666 58
Shanghai Bojing Chemical Co.,Ltd.
+86-21-37122233 +86-13795318958 Candy@bj-chem.com China 497 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 info@tianfuchem.com China 22021 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070 product@chemlin.com.cn CHINA 3013 60
Lianyungang happen teng technology co., LTD
15950718863 wang666xt@163.com CHINA 296 58
career henan chemical co
+86-0371-86658258 sales@coreychem.com China 29959 58
Biochempartner
0086-13720134139 candy@biochempartner.com CHINA 968 58
Nanjing Dolon Biotechnology Co.,Ltd.
18905173768 sales@dolonchem.com CHINA 2972 58
Hubei Jusheng Technology Co.,Ltd.
86-18871470254 linda@hubeijusheng.com CHINA 28229 58

View Lastest Price from AHU-377 manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2022-02-25 AHU-377
149709-62-6
US $16.00 / Kg/Bag 1KG 99% 30KGS Hong Kong Tiansheng New Material Trading Co., Ltd
2022-02-25 AHU-377
149709-62-6
US $5.99 / KG 1KG 99% 100KG Hong Kong Tiansheng New Material Trading Co., Ltd
2019-07-06 AHU-377
149709-62-6
US $100.00 / KG 100G 98% 200KG Career Henan Chemical Co
  • AHU-377
    149709-62-6
  • US $16.00 / Kg/Bag
  • 99%
  • Hong Kong Tiansheng New Material Trading Co., Ltd
  • AHU-377
    149709-62-6
  • US $5.99 / KG
  • 99%
  • Hong Kong Tiansheng New Material Trading Co., Ltd
  • AHU-377
    149709-62-6
  • US $100.00 / KG
  • 98%
  • Career Henan Chemical Co
4-(((2R,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid AHU-377 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-Methyl-5-oxopentan-2-yl)aMino)-4-oxobutanoic acid (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester (2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid AHU-377,149709-62-6 4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoic acid 4-{[(2S,4R)-1-(4-Biphenylyl)-5-ethoxy-4-methyl-5-oxo-2-pentanyl]amino}-4-oxobutanoic acid AHU-77 (2R,4S)-5-([1,1'-Biphenyl]-4-yl)-4-(3-carboxypropanamido)-2-methylpentanoic acid (Sacubitril , AHU-377) LCZ697 4-(((2S,4R)-1-([1,1'-Biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic a Entresto( sacubitril+ valsartan) AHU-37 AHU377; AHU 377; SACUBITRIL LCZ696(valsartan + sacubitril) impurity 4 AHU-377(Sacubitril) AHU-377;AHU 377 ;AHU377 AHU-377 (Sacubitril calcium) 4-《(2S,4R)-I-([I,I'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amin LCZ-696-007-2S4R LCZ-696 Impurity 3 (2R,4S)-4-[(3-Carboxy-1-oxopropyl)amino]-4-[(p-phenylphenyl)methyl]-2-methylbutanoic Acid Ethyl Ester Sacubitril Related Compound 1 [1,1'-Biphenyl]-4-pentanoic acid, γ-[(3-carboxy-1-oxopropyl)amino]-α-methyl-, α-ethyl ester, (αR,γS)- Sacubtril(LCZ696) Sacubitril Control SACUBRITIL AHU-377 USP/EP/BP Sacubitril Standard 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxo... SacubitrilQ: What is Sacubitril Q: What is the CAS Number of Sacubitril Q: What is the storage condition of Sacubitril Q: What are the applications of Sacubitril Sacubitril(AHU-377) valsartan/sacubitril Impurity 1 Sacubitril API 149709-62-6 LCZ 696 LCZ696 intermediates Sacubitril